Amgen vs. Axsome Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?
Amgen generated $8.1 billion in free cash flow in 2025, with a 21% net margin, while Axsome is scaling rapidly but still unprofitable.
Amgen generated $8.1 billion in free cash flow in 2025, with a 21% net margin, while Axsome is scaling rapidly but still unprofitable.
BELLINGS Intelligence Score: 8
Why it matters
This is routine equity investment analysis comparing two healthcare stocks, with no direct impact on credit markets or lending conditions.
Sources
The Motley Fool
Amgen vs. Axsome Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?
Amgen generated $8.1 billion in free cash flow in 2025, with a 21% net margin, while Axsome is scaling rapidly but still unprofitable.